The Global Coalition for Adaptive Research (GCAR) today announced clinical trial results of vitamin C and simvastatin to treat severely ill patients with COVID-19. Simvastatin was shown to have a high probability (96%) of improving outcomes (a combination of survival and length of time patients need support in an intensive care unit) and a 92% chance of improving survival at three months. High-dose vitamin C, however, did not improve outcomes and might be harmful.
The results appeared in JAMA and NEJM respectively, and were presented at the European Society of Intensive Care Medicine in Milan. The studies are part of the ongoing Randomized Embedded Multifactorial Adaptive Platform for Community Acquired Pneumonia (REMAP-CAP) trial.
The results for simvastatin equate to one life saved for every 33 patients treated with the drug. This study included 2684 critically ill patients at 141 hospitals across 13 countries.
“This research will help healthcare professionals internationally to improve the treatment of patients with COVID-19,” said Danny McAuley, professor and consultant in Intensive Care Medicine at the Royal Victoria Hospital and Queen’s University Belfast and lead investigator for the Simvastatin Domain of REMAP-CAP.
Vitamin C is widely available and was used in some settings for the treatment of COVID-19. For this study, through harmonizing two clinical trials—REMAP-CAP and LOVIT-COVID—over 2500 COVID-19 patients in 20 countries took part, including both critically ill and non-critically ill patients in hospital. This is the largest trial examining high-dose vitamin C in COVID-19 and provides evidence that high-dose vitamin C is not beneficial and suggests a high probability that it may be harmful.
“Harnessing the power of global collaboration, the harmonized REMAP-CAP and LOVIT-COVID trials have investigated vitamin C, a potential therapy for COVID-19, and have shown it to be ineffective and probably harmful,” said Neill Adhikari, co-lead investigator for the LOVIT-COVID trial and of the Vitamin C Domain of REMAP-CAP, and of Sunnybrook Health Sciences Centre. “The results from this trial suggest that the use of vitamin C in hospitalized COVID-19 patients should be de-adopted.”
François Lamontagne, co-lead investigator of these trials and of Université de Sherbrooke, added, “The results underscore the health and economic benefits of identifying and abandoning readily available interventions that are ineffective and potentially harmful to patients.”
“The beauty of these trials is in connecting doctors across continents to provide the best possible treatment for the sickest patients with COVID-19, while learning from each other to arrive at evidence-based answers to improve standard of care for patients worldwide,” said Derek Angus, MD, MPH, FRCP, U.S. principal investigator of REMAP and chair of critical care medicine at UPMC and the University of Pittsburgh School of Medicine.
He added that, “To have both of these results from REMAP-CAP published simultaneously is testament to the ability of this trial to efficiently evaluate multiple interventions. Through this horrific pandemic, we’ve pioneered a new way to rapidly address some of the biggest treatment questions, caring for patients today and preparing to respond more nimbly in the future. It has been personally rewarding to be a part of this process and see our aspirational goal become reality.”
REMAP-CAP is a global adaptive platform trial investigating multiple treatments for hospitalized patients with respiratory tract infection. The trial mobilized to evaluate specific treatments for COVID-19 patients in ICUs in early March 2020, and continues to evaluate multiple interventions for COVID-19, influenza, and other causes of severe respiratory infection.
